Top Tweets for #nectin4

Everyone in the Nectin-4 space is talking about who builds the better ADC. The more important question is who builds the bigger commercial lane. As Padcev's label expands into earlier lines, it creates two distinct populations: patients who haven't seen a Nectin-4 ADC yet, and a growing wave who progressed on MMAE. The next-gen programs chasing Padcev are not equally positioned to serve both. I mapped 130 Nectin-4 programs and isolated payload class as the variable. The landscape splits into two commercial theses. MMAE next-gen programs (CRB-701, 9MW2821, BT8009) are running a tolerability thesis. Better conjugation, cleaner PK, fewer side effects. That is a real differentiator in treatment-naive patients. But it is a single-lane strategy. Site-specific conjugation improves delivery, but does not change the warhead that P-gp efflux and tubulin alterations are already evicting from the tumor cell. The ceiling is displacement of Padcev, not expansion beyond it. Topo I programs are running a different thesis. Because their payload is mechanistically orthogonal to MMAE, they can compete in frontline AND pursue the post-MMAE population. Hengrui's SHR-A2102 showed 39% confirmed responses in prior-ADC patients. Lilly published MMAE-resistant model activity for ETx-22 and LY4052031. These are two-lane assets: first-line competition plus a relapsed population MMAE programs structurally cannot enter. That second lane grows every time Padcev succeeds. Every first-line patient who eventually progresses becomes a patient only an orthogonal payload can serve. Topo I benefits from Padcev's success. MMAE next-gen is constrained by it. The payload is not just a safety variable. It is a TAM variable. The Nectin-4 race is not about who builds the best ADC. It is about who builds the widest one. Comment below for a hi-res PDF of the full landscape analysis.